Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

Interest Coverage 2.89
FRX's Interest Coverage is ranked lower than
82% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. FRX: 2.89 )
Ranked among companies with meaningful Interest Coverage only.
FRX' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 2.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

» FRX's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

FRX Guru Trades in

FRX Guru Trades in

Q2 2014

FRX Guru Trades in Q2 2014

Louis Moore Bacon 15,810 sh (New)
Jim Simons 834,300 sh (+18.36%)
First Eagle Investment 806,230 sh (unchged)
Bernard Horn 62,200 sh (unchged)
Carl Icahn Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Bill Nygren Sold Out
Murray Stahl Sold Out
Vanguard Health Care Fund 15,716,666 sh (-23.65%)
Mario Gabelli 183,200 sh (-26.04%)
Jeremy Grantham 170,000 sh (-32.54%)
Dodge & Cox 45,100 sh (-98.84%)
» More
Q3 2014

FRX Guru Trades in Q3 2014

Bernard Horn Sold Out
Mario Gabelli Sold Out
Louis Moore Bacon Sold Out
Jim Simons Sold Out
Jeremy Grantham Sold Out
Dodge & Cox Sold Out
First Eagle Investment Sold Out
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, TSX:VRX » details
Traded in other countries:FQX.Germany,

Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Guru Investment Theses on Forest Laboratories Inc

Bernard Horn Comments on Forest Laboratories - Aug 26, 2014

Pharmaceutical maker Forest Laboratories (FRX) had double digit returns on news of its acquisition by Actavis PLC, the world’s second largest generic drug maker. Prior to this transaction, Forest Labs conducted a company restructuring, increased its product pipeline and initiated a stock buyback, all of which helped boost the stock valuation at the time of Actavis’ $25 billion acquisition bid.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders.

Check out Bernard Horn latest stock trades

Bernard Horn Comments on Forest Laboratories - Aug 07, 2014

Forest Laboratories (FRX) continued to benefit from the news of its acquisition by Actavis PLC, the world’s second largest generic drug maker.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Forest Laboratories Inc - Jun 26, 2014

We closed our position in drug manufacturer Forest Laboratories, Inc. (FRX) as the market reacted positively to the news that Actavis, Inc. PLC would buy Forest Laboratories at a significant premium, and the share price approached our estimate of intrinsic value.

From Diamond Hill Capital's Select Fund Commentary – First Quarter 2014.

Check out Diamond Hill Capital latest stock trades



Valuation & Return


More Statistics

Revenue (TTM) (Mil) $3,659
EPS (TTM) $ 0.61
Short Percentage of Float1.88%
52-Week Range $40.98 - 100.88
Shares Outstanding (Mil)268.44
» More Articles for FRX


Articles On GuruFocus.com
Carl Icahn Turns Up Pressure on AIG, May Propose New Leadership Nov 23 2015 
Bill Nygren's Fourth Quarter Commentary – Oakmark Fund Jan 09 2015 
Bill Nygren’s 4Q 2014 Market Commentary Jan 08 2015 
Bernard Horn Comments on Forest Laboratories Aug 26 2014 
Bernard Horn’s Polaris Global Value Fund 2Q 2014 Message to Our Shareholders Aug 26 2014 
Global Guru Bernard Horn Reports his Top Five from the Second Quarter Aug 22 2014 
Guru of the Year – Carl Icahn’s Top Five Holdings Aug 17 2014 
Bernard Horn Comments on Forest Laboratories Aug 07 2014 
Diamond Hill Capital Comments on Forest Laboratories Inc Jun 26 2014 
GuruFocus Guru of the 2013 Carl Icahn's Top First Quarter Holdings May 15 2014 

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)